To decrease relapse and increase DFS, patients with acute leukemia in CR1 who have no HLA-matched related donor are recommended for ABMT. an M, Feng S, Li C.

Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation. Baron F, Gothot A, Salmon JP, Hermanne JP, Pierard GE, Fillet G, Beguin Y.

Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Andersson BS, Gajewski J, Donato M, Giralt S, Gian V, Wingard J, Tarantolo S, Fernandez H, Hu WW, Blume K, Kashyap A, Forman SJ, Champlin RE

Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement. Martin G, Barragan E, Bolufer P, Chillon C, Garcia-Sanz R, Gomez T, Brunet S, Gonzalez M, Sanz MA.

Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation.  Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A, Vekhoff A, Sadoun A, Stamatoullas A, Fegueux N, Maloisel F, Cahn JY, Reman O, Gratecos N, Berthou C, Huguet F, Kotoucek P, Travade P, Buzyn A, de Revel T, Vilque JP, Naccache P, Chomienne C, Degos L, Fenaux P.

Transfer of immune complexes from erythrocyte CR1 to mouse macrophages. Reinagel ML, Taylor RP.

Intracellular storage and regulated plasma membrane expression of human CR1 in rat basophil leukemia cell transfectants. Jost C, Klickstein L, Wetzler E, Kumar A, Berger M.

Receptors for the third component of complement: their association with maturation stage in non-Hodgkin lymphomas (NHL) and their possible implication with the development of follicular structures. Greil R, Gattringer C, Schulz T, Knapp W, Radaskiewicz T, Dierich MP, Huber H.

Functional characterization of TEL/AML1 fusion protein in the regulation of human CR1 gene promoter. Song H, Kim JH, Rho JK, Park SY, Kim CG, Choe SY.

AML1 and Ets proteins direct the expression of the human CR1 promoter. Kim JH, Lee S, Rho JK, Choe SY.

CR1 is the predominant C3-binding glycoprotein Cole JL, Housley GA Jr, Dykman TR, MacDermott RP, Atkinson JP.

CD4(bright) cells in bone marrow have the same frequency and phenotype as CD123(bright) type 2 dendritic cell (DC) progenitors Waller EK, Rosenthal H, Jones TW, Peel J, Lonial S, Langston A, Redei I, Jurickova I, Boyer MW

Ribosomal proteins sustain morphology,function and phenotype in acute myeloid leukemia blasts. Bassoe CF, Bruserud O, Pryme IF, Vedeler A.

Alternative pathway activation of complement, is observed on mononuclear cells from patients with B CLL  Marquart HV, Gronbaek K, Christensen BE, Svehag SE, Leslie RG.

Expression of the CR1 receptor on human leukemia-derived CD4+ T cell lines. Yaskanin DD, Waxman FJ.

Ability of extracellular nucleotides to modulate the phenotype of myelomonocytic progenitor cells Cowen DS, Berger M, Nuttle L, Dubyak GR.

Phenotype heterogeneity observed in leukemic cell populations is associated with differences in proliferative capacities Campos L, Ffrench M, Guyotat D.

Change of cellular function and phenotype in the course of a suppressor T cell acute lymphocytic leukaemia. Sieber G, Ludwig WD, Teichmann H, Herrmann F, Ruhl H.

Functional characterization of TEL/AML1 fusion protein in the regulation of human CR1 gene promoter.  Song H, Kim JH, Rho JK, Park SY, Kim CG, Choe SY.

AML1 and Ets proteins direct the expression of the human CR1 promoter. Kim JH, Lee S, Rho JK, Choe SY.

Differential timing of gene expression is not essential for proper storage of CR1 and that other sorting mechanisms are involved, which can be studied in RBL-transfectants.  Jost C, Klickstein L, Wetzler E, Kumar A, Berger M.